Gilead Files NDA for HBV Drug. Synta Surprising Merger

Pursuing its goal in treating hepatitis, Gilead Sciences (GILD) is at the finish line of clinical trials on another virus, this time the Hepatitis B virus. HBV not HCV.

Two large Phase 3 trials evaluating once-daily tenofovir alafenamide (TAF) 25 mg in treatment-naïve and treatment-experienced adults with HBeAg-negative and HBeAg-positive chronic hepatitis B virus (HBV) infection met the primary endpoints of non-inferiority to Gilead’s Viread® (tenofovir disoproxil fumarate (TDF) 300 mg. 

The results also demonstrate that Tenofovir alafenamide (TAF) 25 mg improved . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.